SciSparc Ltd.

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company headquartered in Tel Aviv, Israel. The company's core business revolves around the development of therapies for central nervous system (CNS) disorders, with a particular focus on cannabinoid pharmaceuticals. Its mission is to create and enhance a portfolio of technologies and assets based on these compounds, aiming to improve the lives of patients suffering from various neurological conditions.

SciSparc's product pipeline includes several drug candidates in various stages of development. Key programs include SCI-110 for the treatment of Tourette syndrome, Alzheimer's disease and agitation, and obstructive sleep apnea; SCI-210 for autism spectrum disorder and status epilepticus; and SCI-160 for pain. The company also markets CannAmide, an oral formulation for chronic pain and inflammation, and sells a range of hemp seed oil-based products through its subsidiary, SciSparc Nutraceuticals Inc. SciSparc leverages proprietary cannabinoid technologies, including FDA-approved synthetic cannabinoids and new chemical entities, often utilizing the FDA's 505(b)(2) application protocol for expedited development.

Recent developments for SciSparc include its subsidiary NeuroThera Labs being granted a U.S. patent in March 2026 for cannabinoid technology to combat antimicrobial resistance. In the same month, SciSparc signed an agreement to acquire a patent portfolio for endoscopic systems and medical cameras. The company also announced a quantum computing-enabled 3D protein modeling initiative in September 2025, aimed at revolutionizing AI drug discovery. Leadership includes Oz Adler as CEO and CFO, Amitay Weiss as Chairman of the Board, and Itschak Shrem as President.